Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong

Public research footprint of Nanfang Hospital, Southern Medical University, compiled from the ClinicalTrials.gov public registry.

431

Registered studies

193

Active

116

Recruiting now

101

Completed

Stopped or withdrawn

Most-studied conditions

Hepatocellular Carcinoma Non-Resectable · Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With… · Advanced Non-Small Cell Lung Cancer · B Cell Acute Lymphoblastic Leukemia (B-ALL)

Recently updated registry entries

NCT04613596 — Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase… (Recruiting)
NCT07746960 — Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for… (Active Not Recruiting)
NCT07744087 — Modified Single-Incision Plus One-Port Versus Conventional Five-Port Laparoscopic… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Nanfang Hospital, Southern Medical University?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 06, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.